Published on 16 September 2021

Statins in the primary prevention of cardiovascular events and mortality in Switzerland

The Health Technology Assessment (HTA) report on statins for the primary prevention of cardiovascular events and mortality in Switzerland. This is done on the basis of the identified number and quality of the primary literature. Based on the scoping report, the HTA report examines the efficacy, safety, cost-effectiveness and budgetary impact of statin therapy in adults without established cardiovascular disease at low, moderate or (very) high cardiovascular risk compared to no treatment and/or lifestyle adjustment.

Further information

< back to HTA projects

Federal Office of Public Health FOPH

Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
Switzerland - 3003 Bern